Suscribirse

Predicting treatment response to concurrent chemoradiotherapy in squamous cell carcinoma of the cervix using amide proton transfer imaging and intravoxel incoherent motion imaging - 29/11/22

Doi : 10.1016/j.diii.2022.09.001 
Xijia Deng a, 1, Meiling Liu a, 1, Qi Zhou b, Xiujuan Zhao b, Min Li a, Jing Zhang a, Hesong Shen a, Xiaosong Lan a, Xiaoyong Zhang c, Jiuquan Zhang a,
a Department of Radiology, Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing 400030, People's Republic of China 
b Department of Gynecologic Oncology, Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing 400030, People's Republic of China 
c Clinical Science, Philips Healthcare, Chengdu 610041, People's Republic of China 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Highlights

Pretreatment amide proton transfer and intravoxel incoherent motion imaging may be predictors of therapeutic response to concurrent chemoradiotherapy in squamous cell carcinoma of the cervix.
Non-complete remission group demonstrates higher amide proton transfer and   values than complete remission group.
The combination of amide proton transfer and perfusion fraction   value exhibits good diagnostic performance to predict response to concurrent chemoradiotherapy in squamous cell carcinoma of the cervix.

El texto completo de este artículo está disponible en PDF.

Abstract

Purpose

The purpose of this study was to investigate whether amide proton transfer (APT) imaging and intravoxel incoherent motion (IVIM) imaging can predict tumor response to concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervix (SCCC).

Material and methods

Fifty-nine women (mean age, 54 years ± 10 [standard deviation] years; age range: 32−81 years) with pathologically confirmed SCCC underwent magnetic resonance imaging examination of the pelvis including APT and IVIM before concurrent chemoradiotherapy. They were divided into complete remission (CR) and non-CR groups according to therapeutic effect. APT values and IVIM-derived parameters were measured. Intra- and interobserver agreement for IVIM and APT parameters was assessed using intraclass correlation coefficient (ICC) The independent samples t-test was performed to compare the evaluated parameters between the two groups. Predictive performance for treatment response was evaluated by receiver operator characteristic (ROC) curve analysis.

Results

There were 38 and 21 patients in the non-CR and CR groups, respectively. Excellent interobserver and intraobserver agreement were obtained for all IVIM and APT parameters, with ICCs ranging from 0.844 to 0.962. Perfusion fraction ( ) and APT values were lower in the CR group compared with the non-CR group (both P < 0.05). The combination of   and APT values showed good diagnostic performances in predicting response to concurrent chemoradiotherapy, with an area under the ROC curve of 0.852 (95% CI: 0.744–0.961), 79% sensitivity (95% CI: 63–90%), 90% specificity (95% CI: 70–99%) and 83% accuracy (95% CI: 71–92%).

Conclusion

APT and IVIM imaging may serve as noninvasive tools for predicting response to concurrent chemoradiotherapy in patients with SCCC.

El texto completo de este artículo está disponible en PDF.

Keywords : Amide proton transfer imaging, Carcinoma squamous cell, Cervical cancer, Intravoxel incoherent motion imaging, Magnetic resonance imaging, Pelvis


Esquema


© 2022  Société française de radiologie. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 103 - N° 12

P. 618-624 - décembre 2022 Regresar al número
Artículo precedente Artículo precedente
  • Improved myocardial scar visualization with fast free-breathing motion-compensated black-blood T1-rho-prepared late gadolinium enhancement MRI
  • Soumaya Sridi, Marta Nuñez-Garcia, Maxime Sermesant, Aurélien Maillot, Dounia El Hamrani, Julie Magat, Jérôme Naulin, François Laurent, Michel Montaudon, Pierre Jaïs, Matthias Stuber, Hubert Cochet, Aurélien Bustin
| Artículo siguiente Artículo siguiente
  • MRI appearance of combined hepatocellular cholangiocarcinoma
  • Nicolas Billet, Jules Grégory, Maxime Ronot

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.